SIGLEC1 and breast carcinoma: The research initially employed laser microdissection and RNA sequencing to compare gene expression differences between non-metastatic and metastatic lymph nodes in breast cancer patients, identifying significant downregulation of macrophage-related genes (e.g., SIGLEC1, MARCO, and AIM) in metastatic lymph nodes.